ATRELEUTON

/static/temp/default.svg

Search structure


Synonyms	A-85761 A-85761.0 ABBOTT-85761 ABT-761 Atreleuton VIA-2291
Status
Molecule Category	UNKNOWN
UNII	U301T88E1M
EPA CompTox	DTXSID10165598


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	MMSNEKOTSJRTRI-LLVKDONJSA-N
Smiles	C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)N(O)C(N)=O
InChI	InChI=1S/C16H15FN2O2S/c1-11(19(21)16(18)20)2-7-14-8-9-15(22-14)10-12-3-5-13(17)6-4-12/h3-6,8-9,11,21H,10H2,1H3,(H2,18,20)/t11-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H15FN2O2S
Molecular Weight	318.37
AlogP	2.99
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	3.0
Polar Surface Area	66.56
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	22.0

Bioactivity

Mechanism of Action	Action	Reference
Arachidonate 5-lipoxygenase inhibitor	INHIBITOR	PubMed PubMed PubMed


Protein: Arachidonate 5-lipoxygenase Description: Polyunsaturated fatty acid 5-lipoxygenase Organism : Homo sapiens P09917 ENSG00000012779

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Oxidoreductase	-	90-160	-	-	4
Enzyme Protease Serine protease Serine protease SC clan Serine protease S33 family	-	2700	-	-	-

Assay Description	Organism	Bioactivity	Reference
In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay	None	160.0 nM
5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)	None	160.0 nM
Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells	None	23.0 nM
Compound was tested for in vitro inhibition against human whole blood.	Homo sapiens	150.0 nM
Inhibition of 5-lipoxygenase (5-LO) measured as LTB4 production in human whole blood stimulated with calcium ionophore (A23187).	None	160.0 nM
Compound was tested for in vitro inhibition against human PMNL.	Homo sapiens	23.0 nM
Compound was tested for in vitro inhibition against broken RBL-1.	Rattus norvegicus	23.0 nM
Percent inhibition of LTE4 formation in rats from peritoneal fluids at a dose of 200 micro mol/Kg	None	4.0 %
Suppression of calcium ionophore-stimulated LTB4 production in CAD patient whole blood at 100 mg administered daily during phase 2 study for 12 weeks by ELISA relative to baseline	Homo sapiens	80.0 %
Inhibition of 5-LOX (unknown origin) expressed in Escherichia coli BL21-(DE3) pre-incubated for 15 mins before AA substrate addition and measured after 10 mins by HPLC/UV assay	Homo sapiens	90.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL59356
DrugBank	DB12758
FDA SRS	U301T88E1M
PubChem	3086671
SureChEMBL	SCHEMBL2108309

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).